Roche: positive data in pemphigus vulgaris

(CercleFinance.com) - Roche announces positive data for its Phase III Pemphix study, evaluating the efficacy and safety of its MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with pemphigus vulgaris.


The study has reached the primary endpoint and has shown that MabThera is superior to MMF for achieving a complete, lasting remission, the Swiss pharmaceuticals group said, adding that secondary endpoints have also been achieved.

These results will be submitted to different health authorities, including the US FDA. A rare, serious and potentially fatal disease, pemphigus vulgaris is characterised by painful and progressive swelling of the skin and mucous membranes.


Copyright (c) 2019 CercleFinance.com. All rights reserved.